Conference attendance
Pharming Announces Positive Data from Phase II/III Leniolisib Trial Presented at Clinical Immunology Society 2022 Annual Meeting
Pharming Group announces new data from the pivotal Phase II/III trial of leniolisib for the treatment of activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a primary immunodeficiency.
"It is great news that leniolisib has achieved such positive results in this Phase III study in APDS."
- Charlotte Cunningham-Rundles, M.D., Ph.D.,